Fumiya Inoue

Dr. Fumiya Inoue

Narita Redcross Hospital, Narita, Chiba, Japan
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Pediatrics International
Verified
Journal Article
Closed access
NONatsumi Okazaki
Natsumi Okazaki
HIHiroyuki Ikeda
Hiroyuki Ikeda
THTakafumi Honda
Takafumi Honda
KTKazuma Tsuno
Kazuma Tsuno
FIFumiya Inoue
Fumiya Inoue
SIShunji Igarashi
Shunji Igarashi

30 March 2022 in Hematology Reports
Verified
Journal Article
Open access
PDF file
FIFumiya Inoue
Fumiya Inoue
KTKazuki Terada
Kazuki Terada
KFKazuki Furudate
Kazuki Furudate
YNYasushi Noguchi
Yasushi Noguchi
SIShunji Igarashi
Shunji Igarashi
Reports on the treatment of bleeding associated with emicizumab administration are scarce. Herein, we report the case of an eight-year-old boy with moderate hemophilia A with an inhibitor who experienced tonsillar hemorrhage while undergoing emicizumab treatment. He visited our hospital for postprandial bloody vomiting. The activated partial thromboplastin time was 20.8 s; only a small amount of hemorrhage was observed in the retropharyngeal space, and tranexamic acid was administered. He experienced hematemesis on Day 2 of hospitalization, and fiberoptic laryngoscopy confirmed hemorrhage from the posterior tonsil. Varicose vessels were observed at the soft palate, and considering thrombosis, an emergency cauterization was performed instead of bypass therapy. In small children, observing the tonsils is difficult, and the coagulation ability of the patient with hemophilia A is inferior to that of healthy people, even under emicizumab administration. Thus, active hemorrhage assessment and appropriate hemostatic control are necessary.

13 May 2025 in Cardiology in the Young
Verified
Journal Article
Closed access
PDF file
SSShinichiro Sakaki
Shinichiro Sakaki
SOShin Ono
Shin Ono
NSNaka Saito
Naka Saito
FIFumiya Inoue
Fumiya Inoue
TTTomoaki Taruya
Tomoaki Taruya
HUHideaki Ueda
Hideaki Ueda
Severe Ebstein’s disease often necessitates early neonatal surgical intervention, although, in some patients, surgery may be delayed until infancy or later, and medical management may be undertaken instead. Various indicators, such as tricuspid regurgitation flow velocity, have been studied to predict single or biventricular circulation; however, indicators predicting the need for neonatal surgery have not been addressed. We aimed to identify predictive indices for neonatal surgical necessity by analysing the clinical characteristics of those requiring and not requiring neonatal surgery. We enrolled eight patients with severe Ebstein’s disease who were born at our hospital from 2018 to 2023. Four patients underwent neonatal surgery (Group S), whereas four did not (Group F). We compared pregnancy, delivery, and postnatal clinical courses and laboratory indices before and after birth between the groups. The systolic/diastolic time ratio, an index of ventricular function calculated from the TR waveform of echocardiography at birth, was significantly prolonged in Group S [2.18 ± 0.31 vs. 1.72 ± 0.20 in Group F ( p = 0.043)]. The area under the receiver operating characteristic curve was 0.94, with a threshold systolic/diastolic time ratio value of 1.99 using Youden’s method. This ratio predicted neonatal surgery necessity with 100% sensitivity and 75% specificity. Despite the small sample size, we demonstrated that the systolic/diastolic time ratio is a valuable predictive index of ventricular function and prognosis in severe Ebstein’s disease patients. A systolic/diastolic time ratio <2, determined from the tricuspid regurgitation waveform on echocardiography at birth, supports patient monitoring without surgical intervention through the newborn period and beyond.